TYRA BIOSCIENCES INC (TYRA) Stock Price, Quote, News and Overview
NASDAQ:TYRA - Nasdaq - US90240B1061 - Common Stock - Currency: USD
TYRA Quote, Performance and Key Statistics
10.02
+0.55 (+5.81%)
The current stock price of TYRA is 10.02 USD. In the past month the price decreased by -2.81%. In the past year, price decreased by -36.06%.
TYRA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.5 | 313.20B | ||
| AMGN | AMGEN INC | 14.02 | 149.41B | ||
| GILD | GILEAD SCIENCES INC | 23.08 | 132.62B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1698 | 126.59B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.88 | 64.26B | ||
| ARGX | ARGENX SE - ADR | 319.7 | 36.31B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.48B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.60B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.85B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 24.51B | ||
| NTRA | NATERA INC | N/A | 20.08B | ||
| BIIB | BIOGEN INC | 7.17 | 17.30B |
Related stock screener links
About TYRA
Company Profile
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The company is headquartered in Carlsbad, California and currently employs 49 full-time employees. The company went IPO on 2021-09-15. The company is focused on developing precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. Its initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. Its lead product candidate, TYRA-300, is an investigational, oral, FGFR3-selective inhibitor being evaluated in an international, multi-center, open label Phase 1 clinical study, SURF301. Its second oncology product candidate, TYRA-200, is an investigational, oral, FGFR1/2/3 inhibitor with potency against activating FGFR2 gene alterations, and clinically important molecular brake and gatekeeper resistance mutations.
Company Info
TYRA BIOSCIENCES INC
2656 State Street
Carlsbad CALIFORNIA US
CEO: Todd Harris
Employees: 49
Company Website: https://tyra.bio/
Investor Relations: http://tyrabio.investorroom.com/
Phone: 16197284760
TYRA BIOSCIENCES INC / TYRA FAQ
What is the stock price of TYRA BIOSCIENCES INC today?
The current stock price of TYRA is 10.02 USD. The price increased by 5.81% in the last trading session.
What is the ticker symbol for TYRA BIOSCIENCES INC stock?
The exchange symbol of TYRA BIOSCIENCES INC is TYRA and it is listed on the Nasdaq exchange.
On which exchange is TYRA stock listed?
TYRA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TYRA BIOSCIENCES INC stock?
14 analysts have analysed TYRA and the average price target is 31.04 USD. This implies a price increase of 209.75% is expected in the next year compared to the current price of 10.02. Check the TYRA BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TYRA BIOSCIENCES INC worth?
TYRA BIOSCIENCES INC (TYRA) has a market capitalization of 531.96M USD. This makes TYRA a Small Cap stock.
How many employees does TYRA BIOSCIENCES INC have?
TYRA BIOSCIENCES INC (TYRA) currently has 49 employees.
What are the support and resistance levels for TYRA BIOSCIENCES INC (TYRA) stock?
TYRA BIOSCIENCES INC (TYRA) has a support level at 8.67 and a resistance level at 16.1. Check the full technical report for a detailed analysis of TYRA support and resistance levels.
Should I buy TYRA BIOSCIENCES INC (TYRA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TYRA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TYRA, evaluating the profitability, health, valuation and growth aspects
- TYRA BIOSCIENCES INC (TYRA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TYRA BIOSCIENCES INC (TYRA) Sales and EPS estimates to see what analysts future expectations are.
- TYRA BIOSCIENCES INC (TYRA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TYRA BIOSCIENCES INC (TYRA) Insider and Institutional Ownership to learn about the owners and their transactions.
- TYRA BIOSCIENCES INC (TYRA) Stock Chart to make your own analysis
- TYRA BIOSCIENCES INC (TYRA) Latest news and press-releases to stay up to date.
Does TYRA BIOSCIENCES INC (TYRA) stock pay dividends?
TYRA does not pay a dividend.
When does TYRA BIOSCIENCES INC (TYRA) report earnings?
TYRA BIOSCIENCES INC (TYRA) will report earnings on 2025-05-01, after the market close.
What is the Price/Earnings (PE) ratio of TYRA BIOSCIENCES INC (TYRA)?
TYRA BIOSCIENCES INC (TYRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.51).
What is the Short Interest ratio of TYRA BIOSCIENCES INC (TYRA) stock?
The outstanding short interest for TYRA BIOSCIENCES INC (TYRA) is 8.7% of its float. Check the ownership tab for more information on the TYRA short interest.
TYRA Technical Analysis
TYRA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TYRA. No worries on liquidiy or solvency for TYRA as it has an excellent financial health rating, but there are worries on the profitability.
TYRA Financial Highlights
Over the last trailing twelve months TYRA reported a non-GAAP Earnings per Share(EPS) of -1.51. The EPS increased by 6.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.79% | ||
| ROE | -25.2% | ||
| Debt/Equity | 0 |
TYRA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to TYRA. The Buy consensus is the average rating of analysts ratings from 14 analysts.